Navigation Links
Winners of WuXi PharmaTech Awards Inducted into Prestigious Academies
Date:12/23/2013

SHANGHAI, Dec. 23, 2013 /PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device research and development outsourcing company with operations in China and the United States, congratulates five winners of the WuXi PharmaTech Life Science and Chemistry Awards on their inductions as new members of the highly prestigious Chinese Academy of Sciences (CAS) and Chinese Academy of Engineering (CAE).

CAS inducted four former WuXi award winners: Professors Jiahuai Han of Xiamen University (2009 award winner), Xiaoming Feng of Sichuan University (2010 award winner), George Fu Gao of the Institute of Microbiology at the CAS (2011 award winner), and Jie He of the Oncology Hospital at the Chinese Academy of Medical Sciences (2011 award winner). Professor Guangji Wang of China Pharmaceutical University (2008 award winner) was inducted into the CAE.

The WuXi PharmaTech Life Science and Chemistry Awards are the first nationwide scientific award in China established by a life science enterprise with the mission of fostering early innovation and encouraging the pursuit of excellence in the life sciences. Eight of the 95 scholars awarded between the awards' inception in 2007 and 2012 were later elected to the CAS or the CAE.

"We are proud to see the excellent work of five of our former award winners recognized by the CAS and the CAE," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "Their groundbreaking scientific research provides great insights into diseases and holds promise for better cures. The inductions are very well deserved."

About WuXi PharmaTech

As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi AppTec is the name for the operating subsidiaries of WuXi PharmaTech. For more information, please visit: http://www.wuxiapptec.com.

WuXi PharmaTech's Contacts:

Ronald Aldridge, Director of Investor Relations
+1 (201) 585-2048
ron_aldridge@wuxiapptec.com

Aaron Shi, Associate Director, Corporate Communications
+86-21-5046-4362
aaron_shi@wuxiapptec.com


'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Elsevier and Algerian Ministry of Higher Education and Research Announce the Winners of 2013 Algerian Scopus Award Winners
2. Biocom Announces 2013 DeviceFest & Expo Award Winners
3. Allscripts Announces Winners of the Open App Challenge
4. Allscripts Announces 2013 Client Excellence Award Winners
5. UBM Canon and MD+DI Proudly Announce 27 Innovative Products as Winners of the 2013 Medical Design Excellence Awards
6. 2013 Facility of the Year Awards (FOYA) Winners Announced
7. Cochlear Americas Announces 2013 Graeme Clark and Anders Tjellstrom Scholarship Winners
8. Seahorse Bioscience Announces Asia Mito 2012 Travel Award Winners Advancing Cell Metabolism Research
9. Archbishop Desmond Tutu and the International Childrens Peace Prize Winners Launch Remember2015
10. Elsevier and Australasian Research Management Society Announce Winners of the 2012 Scopus Young Researcher of the Year Awards
11. Telemedicine, Teleradiology, and Telemonitoring Look Like Winners in the New Healthcare Economy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)...   Pairnomix, LLC, a genetic research company and ... the White House, today announced that findings from its first ... candidate therapies for a patient with epileptic encephalopathy caused by ... at the 70 th Annual Meeting of the ... , December 2-6, 2016.  Pairnomix, unique process involves ...
(Date:12/4/2016)... EAST HANOVER, N.J. , Dec. 3, 2016 /PRNewswire/ ... SEG101 (crizanlizumab, formerly SelG1), an anti-P-selectin antibody, reduced the ... by 45.3% compared to placebo (1.63 vs 2.98, p=0.010) ... Novartis today announced that the data are being featured ... American Society of Hematology (ASH) Annual Meeting and ...
(Date:12/4/2016)... Dec. 3, 2016  Findings from a Novartis ... CTL019, an investigational chimeric antigen receptor T cell ... young adult patients with B-cell acute lymphoblastic leukemia ... session at the 58th American Society of Hematology ... p.m.). The global Phase II study found that ...
Breaking Medicine Technology:
(Date:12/4/2016)... ... December 03, 2016 , ... The Lymphoma Research Foundation ... research and serving the lymphoma community through a comprehensive series of education programs, ... Event in New York City, with long-time partners The Paul Foundation, on November ...
(Date:12/4/2016)... Aliso Viejo, California (PRWEB) , ... December 04, ... ... self-animating lower third presets that have new attractive animation styles with unique displacement ... Pro3rd Displace features 30 pre-animated lower third designs. Choose from a variety of ...
(Date:12/2/2016)... , ... December 02, 2016 , ... Lori G. ... Traurig, LLP’s Atlanta office, will speak at the American Conference Institute’s 21st Drug ... Traurig is also a Lead Sponsor of the conference. , Cohen, who chairs the ...
(Date:12/2/2016)... ... December 02, 2016 , ... Advanced Inc., a leading provider of ... Bice, CPA, MBA to serve as Advanced Inc.’s Chief Financial Officer, effective December 1, ... Jason brings extensive financial and operational leadership experience to Advanced Inc. He began his ...
(Date:12/2/2016)... PA (PRWEB) , ... December 02, 2016 , ... With ... struggling through rehabilitation of an injury, patients must find the one that works for ... his pain, he created a machine that worked and decided to share it with ...
Breaking Medicine News(10 mins):